|
|
|
|
 |
|
|
| |
|
 |
Latest News / Articles |
 |
|
|
|
|
 |
Login |
 |
|
|
|
|
|
|
|
We are a biotechnology company dedicated to technology development having application for rapidly and efficiently determining the safety of new drugs prior to first administration in humans (Phase I clinical trial). Specifically, we offer
CELL LINES CONTAINING REPORTER GENE CONSTRUCTS
TO EXAMINE RECEPTOR ACTIVATION.
We are an industry pioneer and the only company commercializing this technology resulting from "know-how" and our intellectual property position. We have developed systems useful for determining the potential of new molecular entities (drugs) to cause a drug-drug reaction or adverse drug reactions. The primary application of the cell lines is to screen for Nuclear Receptor Activation. Of interest to most pharmaceutical companies is screening drugs for PXR binding, which in turn increases the expression of CYP3A4, CYP2Cs, P-Glycoprotein, and a number of other drug and bile acid transporters. Many companies are also interested in screening for Ah receptor (dioxin response element: CYP1A) binding and activation. Because of their role in controlling endogenous biochemical pathways, these receptors are of vital importance in screening for physiological alterations caused by new chemical entities. Moreover, they are excellent predictors of drug-drug interactions and thus are important to safety analysis. Puracyp holds exclusive global rights to human SXR/PXR use in screening xenobiotics for their ability to activate the receptor. Due to our patent position, and years of “know-how” development, we are the only company in the world that can offer PXR containing cell lines.
Read about Dr. Raucy, CSO being featured in Genetic Engineering News
|
|
|
|
|
